Fostemsavir (BMS-663068) is an experimental HIVentry inhibitor and a prodrug of temsavir (BMS-626529). It is under development by Bristol-Myers Squibb for use in the treatment of HIV infection. By blocking the gp120 receptor of the virus, it prevents initial viral attachment to the host CD4+ T cell and entry into the host immune cell; its method of action is a first for HIV drugs. Because it targets a different step of the viral lifecycle, it offers promise for individuals with virus that has become highly resistant to other HIV drugs. Since gp120 is a highly conserved area of the virus, the drug is unlikely to promote resistance to itself via generation of CD4-independent virus.
To reduce the risk of recurring DVT and PE after initial therapy.
Atrial fibrillation
Apixaban is recommended by the National Institute for Health and Clinical Excellence for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation and at least one of the following risk factors: prior stroke or transient ischemic attack, age 75 years or older, diabetes mellitus, or symptomatic heart failure.
Opportunities for commercial and industrial (C&I) energy storage are growing, and customers need safe, reliable battery systems that maximise value throughout their lifecycle, says Cubenergy's Chris Wu ....
FPT INDUSTRIAL'S eBM 5, ITS LATEST BMS TECHNOLOGY, HAS ACHIEVED THE TOP... This enhanced approach has led to the TÜV SÜDASIL C certification and has also further strengthened our confidence in the reliability and safety of our BMS product.".
How we act upon that responsibility is outlined in our industry-leading DanonePolicy for the Marketing of Breast Milk Substitutes (BMS) (or BMS Policy), which sets out our global standards for the responsible marketing of baby formula.